NEW YORK (GenomeWeb) – Illumina and the Mayo Clinic said today that they have formed a partnership to study and interpret genetic variants involved in disease.
Under the terms of the deal, Mayo will test Illumina's BaseSpace Clarity LIMS in specific laboratories to determine how well it tracks and integrates workflows in the lab. Mayo will also deploy Illumina's cloud-based genomics computing environment, BaseSpace Sequence Hub, for data analysis and management, and its cloud-based interpretation and reporting platform BaseSpace Variant Interpreter. Mayo will use these tools to annotate and interpret genetic variants to study their potential role in the development and progression of various diseases.
Further terms of the collaboration were not disclosed.
"Through this relationship, we will be able to generate large volumes of genomic information, interrogate the data, and then compare it to what's known about those variants and those genetic aberrations in real time, saving our geneticists time," William Morice, chair of Mayo's department of laboratory medicine and pathology and president of Mayo Medical Laboratories, said in a statement. "We are pleased to work with Illumina and to leverage each other's expertise in genetic sequencing and analysis."